Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 14/20 | 0.50 |
| ▸ | ESR1 | P03372 | 13/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.50 |
| ▸ | TOP1 | P11387 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780841 | 1.00 | HRAS (0.50) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7503370 | 0.93 | HRAS (0.61) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL3685005 | 0.93 | HRAS (0.61) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7498136 | 0.92 | HRAS (0.60) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7504933 | 0.92 | HRAS (0.60) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7507423 | 0.92 | HRAS (0.60) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7501006 | 0.92 | HRAS (0.60) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL3454819 | 0.92 | KDM4E (0.61) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7510696 | 0.92 | HRAS (0.60) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7506162 | 0.92 | HRAS (0.60) | HRASESR1ESR2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889624-B1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-12-15 | — | — | EP | claimed |
| US-7642229-B2 | Pharmaceutical composition and a product which includes a substituted acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-05 | — | — | US | claimed |
| US-20090074757-A1 | Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-03-19 | — | — | US | claimed |
| EP-1299110-B1 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ANTIMETABOLITES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2008-11-26 | — | — | EP | claimed |
| EP-1889624-A2 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-02-20 | — | — | EP | claimed |
| EP-1868599-A1 | ANTITUMOR COMBINATION COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ANTIBODIES INHIBITING GROWTH FACTORS OR THEIR RECEPTORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2007-12-26 | — | — | EP | claimed |
| WO-2006108763-A1 | ANTITUMOR COMBINATION COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ANTIBODIES INHIBITING GROWTH FACTORS OR THEIR RECEPTORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2006-10-19 | — | — | WO | claimed |
| US-20060084612-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2006-04-20 | — | — | US | claimed |
| US-7030089-B2 | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione | PHARMACIA ITALIA S.P.A. (IT) | 2006-04-18 | — | — | US | claimed |
| EP-1461083-B1 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2006-03-29 | — | — | EP | claimed |
| US-20040092453-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2004-05-13 | — | — | US | claimed |
| US-20030180383-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2003-09-25 | — | — | US | claimed |
| US-20030162722-A1 | Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2003-08-28 | — | — | US | claimed |
| WO-2003055522-A1 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2003-07-10 | — | — | WO | claimed |
| EP-1303307-A2 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ALKYLATING AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-04-23 | — | — | EP | claimed |
| EP-1292290-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACRYLOYL DISTAMYCIN DERIVATIVES AND TOPOISOMERASE I AND II INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2003-03-19 | — | — | EP | claimed |
| EP-1280527-A2 | USE OF SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES IN THE TREATMENT OF TUMORS ASSOCIATED WITH HIGH LEVELS OF GLUTATHIONE | Pharmacia Italia S.p.A. (IT) | 2003-02-05 | — | — | EP | claimed |
| WO-2001097789-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACRYLOYL DISTAMYCIN DERIVATIVES AND TOPOISOMERASE I AND II INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| WO-2001097790-A2 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ALKYLATING AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| WO-2001085144-A2 | USE OF SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES IN THE TREATMENT OF TUMORS ASSOCIATED WITH HIGH LEVELS OF GLUTATHIONE | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092453-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | HDGF, TUBB1, BCOR | HRAS 541/4885ESR1 3539/4885ESR2 1737/4885 |
| US-20060084612-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors | STK4, DSTYK, MTOR | HRAS 513/4885ESR1 3232/4885ESR2 1839/4885 |
| US-20030162722-A1 | Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors | TOP2A, TOP1, TOP2B | HRAS 1977/4885ESR1 3510/4885ESR2 2241/4885 |
| US-20090074757-A1 | Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors | HDGF, MET, HGF | HRAS 285/4885ESR1 2554/4885ESR2 593/4885 |
| US-20030180383-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents | GSTM2, GSTP1, GSTA1 | HRAS 18/4885ESR1 4231/4885ESR2 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.